Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exonhit has received €1,928,000 from OSEO, as part of its involvement in a consortium led by ERYTECH Pharma and funded under the program for Strategic Industrial Innovation.
Subscribe to our email newsletter
At the beginning of the project during the first semester of 2012, an amount of €1,126,000 was paid to Exonhit.
The consortium aims at developing new therapies for the enzymatic treatment of chemo- or radio-resistant cancers, and tools enabling personalized care of patients.
The total amount awarded to the consortium amounts to approximately €10.7m. The project is expected to last eight years.
Exonhit CEO Loic Maurel said the financial support of OSEO will enable the company to move towards solutions better adapted to the commercialization of diagnostics developed using Genome Wide SpliceArray (GWSA) technology.
Exonhit will participate in both phases of the project using its proprietary GWSA technology, to study tumor transcriptomic profiles in the initial phase, followed by the use of its capabilities in diagnostic test development to translate these profiles into a companion diagnostic.
The company will be responsible for the identification of biomarkers of susceptibility to therapeutic response and the development of an enzymatic therapy companion diagnostic that will identify responders.